Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany (3A)

Institute for Heart Attack Research Foundation (IHF)

Status: Completed

Conditions: Arterial Hypertension

Treatments: Drug: No RAS-inhibition; Drug: Aliskiren; Drug: ACE-I/ARB

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01454583

3A-Registry

Details and patient eligibility

About

In Germany nearly half of the population present elevated values of blood pressure, with - as a result of lifestyle factors and a growing average age - further increasing numbers.

Consequences of arterial hypertension may be cardiovascular diseases, cerebrovascular events, and renal insufficiency. Thus, hypertension therapy focuses on the reduction of these complications.

The aims of the 3A-registry are the characterization of outpatients with hypertension, their diagnostic procedures and medical treatment (esp. with renin inhibitors), therapy compliance and success, clinical events, and an assessment of overall guideline adherence in the treatment of these patients.

Patients fulfilling the relevant criteria are enrolled and followed up by their general practitioner or medical specialist.

Enrollment: 15,337 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• treatment as outpatient
• arterial hypertension
• treatment with a renin inhibitor, ACE inhibitor, ARB, or without RAS blockade
• informed consent

Exclusion criteria

• foreseeable difficulties to perform follow up

Trial design

15,337 participants in 3 patient groups

Aliskiren

Description:

Patients getting Aliskiren at baseline

Treatment:

Drug: Aliskiren

ACE-I/ARB

Description:

Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren

Treatment:

Drug: ACE-I/ARB

No RAS-inhibition

Description:

Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)

Treatment:

Drug: No RAS-inhibition